11 hours Ago fatido/E+ via Getty Images Lantheus Holdings ( NASDAQ: LNTH ) announced on Wednesday that its PET imaging agent MK-6240 met its co-primary endpoints in two pivotal studies designed to assess its sensitivity and specificity in the diagnosis of Alzheimer’s disease. The Bedford, Massachusetts-based company intends to include these.
